The fluid structure of Golgi

The intracellular Golgi apparatus was believed to be a fixed structure that processed proteins for secretion in an assembly-line fashion. But two papers in November 12 Journal of Cell Biology, show that the entire Golgi apparatus is a dynamic structure and suggest that most, if not all, Golgi protein elements cycle through endoplasmic reticulum (ER) in interphase cells.Suzanne Miles and colleagues at Virginia Tech, Blacksburg, US, compared the effect of protein inhibition and ER exit blocking on

By | November 16, 2001

The intracellular Golgi apparatus was believed to be a fixed structure that processed proteins for secretion in an assembly-line fashion. But two papers in November 12 Journal of Cell Biology, show that the entire Golgi apparatus is a dynamic structure and suggest that most, if not all, Golgi protein elements cycle through endoplasmic reticulum (ER) in interphase cells.

Suzanne Miles and colleagues at Virginia Tech, Blacksburg, US, compared the effect of protein inhibition and ER exit blocking on the distribution of 12 different proteins from the Golgi apparatus, including glycosyltransferases and putative matrix proteins. They observed a redistribution of Golgi proteins away from the nucleus only in the presence of ER exit blockers but not in the presence of protein synthesis inhibitors (J Cell Biol 2001, 155:543-556).

"These results suggest that maintenance of a juxtanuclear Golgi apparatus requires protein cycling per se, rather than replacement of degraded components," said Miles.

A second paper, by Theresa Ward and colleagues from the National Institute of Child Health and Human Development, Bethesda confirms these findings. Ward et al. showed that when ER to Golgi transport is inhibited the Golgi structure disassembles, leaving no residual Golgi membranes (J Cell Biol 2001, 155:557-570).

"Potential practical applications of these findings include delivery of medicines to very specific locations in cells, and new ways to modify the cells to produce compounds for use in pharmaceuticals and for other uses", concluded Brian Storrie, senior author from the Virginia Tech group.

Popular Now

  1. Consilience, Episode 3: Cancer, Obscured
  2. RNAi’s Future in Drug-Target Screening
    News Analysis RNAi’s Future in Drug-Target Screening

    A recent CRISPR study contradicted years of RNA interference research on a well-studied cancer drug target. But is it the last nail in the coffin for RNAi as a screening tool? 

  3. A History of Screening for Natural Products to Fight Cancer
  4. Human Cord Plasma Protein Boosts Cognitive Function in Older Mice
AAAS